Health
Utah mom fights for her daughter’s access to discontinued diabetes medication: ‘Life-saving'
A Utah mother is fighting for her teenage daughter’s access to diabetes medicine.
Ruby Smart, 15, has been taking Levemir (detemir) insulin since she was diagnosed with type 1 diabetes more than two years ago.
“Levemir is uniquely suited to her situation,” Alison Smart, the girl’s mother, told Fox News Digital in an interview.
The family was stunned when Novo Nordisk, the Denmark-based manufacturer of Levemir, announced in November 2023 that the drug was being discontinued.
YOUR DIABETES RISK MAY DOUBLE IF YOU EAT THIS FOOD TWICE A WEEK, SAY HARVARD RESEARCHERS
Smart has now made it her mission to convince Novo Nordisk to continue making Levemir — or to find a pharmaceutical company to create a biosimilar (generic) alternative.
Levemir is a long-acting basal insulin that’s injected once or twice a day to control high blood sugar in adults and children with diabetes, according to Novo Nordisk’s website.
Utah mother Alison Smart (in green sweater, pictured with Ruby Smart, age 15) is fighting for her teenage daughter’s access to diabetes medicine. (Alison Smart/iStock)
For Smart’s daughter, an active athlete who plays on the tennis team at Woods Cross High School, Levemir has enabled her to continue with her regular activities while controlling her diabetes.
While there are a couple of other types of basal insulin on the market, Smart said Levemir is best suited to her daughter’s needs.
DEPRESSION IDENTIFIED AS ‘CONTRIBUTING CAUSE’ OF TYPE 2 DIABETES RISK, SAYS NEW STUDY: ‘IMPORTANT’ FINDINGS
“Levemir is unique in that it is a relatively shorter-acting basal insulin, making it ideal for those with fluctuating basal insulin needs, including teenagers, menstruating women, pregnant women and athletes,” she said.
“The two remaining insulins also have side effects we don’t worry about when using Levemir.”
“She’s super active and plays tennis almost every day,” Smart said of her daughter, pictured here. “The pump was fine for daily activity, but for tennis tournament days, it didn’t work.” (Alison Smart)
They did try an insulin pump for a few weeks, which is a wearable device that provides a steady flow of insulin to the body. But Smart said it was not compatible with her daughter’s high activity levels.
“She’s super active, and plays tennis almost every day,” Smart said. “The pump was fine for daily activity, but for tennis tournament days, it didn’t work.”
TYPE 2 DIABETES A MUCH GREATER RISK FOR ‘NIGHT OWLS’ THAN FOR EARLY BIRDS, A ‘STARTLING’ NEW STUDY FINDS
Smart is advocating for people to be able to choose.
“The bottom line is that Levemir works for us,” she said. “Our lives are much easier and less complex on a regimen of multiple daily injections using Levemir insulin.”
Reasons for discontinuation
Novo Nordisk provided three main reasons for why it’s discontinuing Levenir.
“After careful consideration, we made this decision because of global manufacturing issues, decreasing patient coverage, and because we are confident that patients in the U.S. will be able to find alternative treatments,” the company said in a press release.
Novo Nordisk announced in Nov. 2023 that Levemir would be discontinued. “During this time, we strongly encourage that health care professionals and patients discuss transitioning to alternative treatment options prior to the discontinuation date,” the company said in a statement. (LISELOTTE SABROE/Scanpix Denmark/AFP)
When contacted by Fox News Digital, Novo Nordisk provided the following recommendation to doctors and patients.
“During this time, we strongly encourage that health care professionals and patients discuss transitioning to alternative treatment options prior to the discontinuation date. Novo Nordisk, along with other companies, provides a number of alternative treatment options for people living with diabetes who require basal insulin.”
The company suggested that patients switch to other basal insulin options, including but not limited to Basaglar, Insulin Degludec, Insulin Glargine U-300, Lantus, Rezvoglar, Semglee, Toujeo and Tresiba.
“The other options for basal insulin are not equal and are not sufficient — they have different side effects and different qualities.”
Many parents, however, say these alternatives are not the same.
“The other options for basal insulin are not equal and are not sufficient — they have different side effects and different qualities,” Smart told Fox News Digital.
“They’re not as flexible, and not as easy to use with someone who has varying basal insulin needs, like a teenager.”
Alison Smart, far right, is pictured with two other parents of teens with type 1 diabetes in Washington, D.C. (Alison Smart)
Other parents are also concerned about being forced to switch medications.
Jaime Losinski, a mother in Tampa, Florida, has a 14-year-old son with type 1 diabetes. He’s been taking Levemir for years.
“Levemir is a valuable insulin for children and teens, who have ever-changing insulin needs as they grow,” she told Fox News Digital.
OZEMPIC-WEGOVY PILL MAY BE ON THE WAY: TRIAL SHOWS PROMISING RESULTS FOR NEW WEIGHT LOSS TABLET
“Levemir’s action profile makes it perfect for patients who need to make rapid and continual changes,” she went on.
“An insulin such as Lantus or Tresiba, which the industry tells us to ‘just switch to,’ lasts far too long in the system for someone like him and would be dangerous overnight,” she said. “They also come with side effects, all of which he experienced when we tried them both shortly after his diagnosis seven years ago.”
Smart teamed up with other parents to form the Alliance to Protect Insulin Choice. She has also visited Washington, D.C., twice to meet with senators and congressional representatives. (Alison Smart)
Although Levemir is expected to be available until Dec. 2024, Smart said providers have warned her to “expect supply disruption” in the meantime.
Some insurance companies have already stopped coverage of the drug due to the discontinuation.
Smart received a letter from her insurance company in November saying Levemir would not be on her plan any longer. They later agreed to add it back on — but only if she paid a premium.
‘Not as cut and dry as it might seem’
Erin Palinski-Wade, a certified diabetes educator in New Jersey, said the discontinuation of Levemir is “understandably surprising and frustrating” for patients who rely on this brand of insulin.
“Although there are other forms of long-acting insulin on the market, each has its own slight differences, such as peak times, which can have a significant impact on blood glucose management during the day,” she told Fox News Digital.
“For children and teens, there may be greater fluctuations in blood sugar.”
“Transitioning from one brand of insulin to another is not as cut and dry as it might seem, and can lead to periods of high blood sugar or hypoglycemia episodes (dangerously low blood sugars) as the adjustment occurs,” Palinski-Wade added.
For parents who rely on Levemir, the expert recommended working with a physician, endocrinologist and/or dietitian to create the “best transition plan possible” to minimize fluctuations in blood sugar while finding an alternative that works best.
“Levemir is a valuable insulin for children and teens, who have ever-changing insulin needs as they grow,” a mother said. (iStock)
When transitioning to a new insulin, increased testing of glucose levels is needed to prevent and correct highs and lows as they occur, Palinski-Wade noted.
“This is especially important for children and teens, as there may be greater fluctuations in blood sugar due to activity, growth and hormone fluctuations,” she said.
AI HEALTH CARE PLATFORM PREDICTS DIABETES WITH HIGH ACCURACY BUT ‘WON’T REPLACE PATIENT CARE’
Tanya Freirich, a certified diabetes educator in New York City working as The Lupus Dietitian, agreed that the closest replacement in terms of duration of action is Lantus (insulin glargine).
“One of the differences is the peak time,” she told Fox News Digital.
“Lantus peaks [or lowers the blood sugar the most] at six hours after administration, while Levemir peaks at eight to 10 hours after administration. This difference would affect the appropriate timing for the medication to prevent dangerous blood sugar lows.”
Dr. Marc Siegel, clinical professor of medicine at NYU Langone Medical Center and a Fox News medical contributor, said he is also disappointed by the news of the discontinuation. (Fox News)
Dr. Marc Siegel, clinical professor of medicine at NYU Langone Medical Center and a Fox News medical contributor, said he is also disappointed by the news of the discontinuation.
“It is based on supply chain and production issues rather than a problem with the product,” he told Fox News Digital.
“We definitely need biosimilar versions to replace it,” he said. “It can be life-saving.”
“It is based on supply chain and production issues rather than a problem with the product.”
“Some patients really need a version of insulin and Levemir may be their best option.”
Although Levemir is “very similar” to Lantus, Siegel said, it has two important differences: “It causes less weight gain and less hypoglycemia (low glucose).”
Advocating for access
After Novo Nordisk’s November announcement of the discontinuation, Smart sprung into action.
She set up an online petition and began contacting the Food and Drug Administration and the World Health Organization.
“This drug is on the World Health Organization’s list of essential medicines,” she said. “I just couldn’t wrap my head around the possibility of this happening and people not being as outraged as I was.”
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
Smart also teamed up with other parents to form the Alliance to Protect Insulin Choice. She has visited Washington, D.C., twice to meet with senators and congressional representatives.
“Our goal is to have Novo Nordisk slow down the discontinuation, and produce Levemir insulin for a few years until a biosimilar is widely available,” she said.
“We would like to find a biosimilar manufacturer to make this insulin, so it stays available.”
An insulin pump, a wearable device that provides a steady flow of insulin to the body, was not compatible with her daughter’s high activity levels, said Smart of Utah. (iStock)
While Smart recognizes that the medication may not be available “forever,” she aims to slow down the discontinuation and keep Levemir available for a few more years — “because it will take that long to get a biosimilar up and running.”
Smart’s efforts have also caught the attention of billionaire Mark Cuban, who expressed his willingness to partner with Novo Nordisk to continue producing Levemir.
When contacted by Fox News Digital, Cuban said that his pharmaceutical company, CostPlus Drug Company, is “trying to figure out a way to source [Levemir].”
“We aren’t there yet, but we are trying,” he said.
For more Health articles, visit www.foxnews.com/health.
NEWYou can now listen to Fox News articles!
An American woman who may have been exposed to hantavirus on board the MV Hondius cruise ship is now being forced to quarantine at a facility in Omaha, Nebraska.
Angela Perryman, 47, anticipated having to stay at the National Quarantine Unit for a short time after arriving last week, but on Monday she was served with a federal order to remain quarantined for at least two more weeks, she shared with The New York Times.
The order mandates that Perryman remains in the facility until May 31, which would be a total of 21 days after her arrival. Officials told her that any attempts to leave could result in law enforcement involvement, she said.
CRUISE PASSENGER SHOWS LIFE INSIDE NEBRASKA QUARANTINE AFTER HANTAVIRUS EXPOSURE SCARE
“They won’t let us isolate at home,” Perryman, who lives in Ecuador but has a home in South Florida, told the news outlet. “We’re being kept in a secured facility and threatened if we try to leave.”
U.S. passengers from the cruise ship MV Hondius, affected by a hantavirus outbreak, arrive at the University of Nebraska Medical Center Davis Global Center, in Omaha, Nebraska, on May 11, 2026. (Nikos Frazier/Omaha World-Herald via Getty Images)
The woman shared that she received a negative hantavirus test result and is not experiencing symptoms. However, she said she did briefly speak with a passenger who later died from the disease.
The federal order, which the passenger shared with the Times, states that it could “constitute a probable source of infection to other people” if Perryman were to leave the facility to travel to another state.
HANTAVIRUS DEATHS ON CRUISE SHIP HIGHLIGHT DANGERS OF RODENT-BORNE DISEASE
After receiving a medical review within 72 hours, Perryman was told she can appeal the order. She told the Times that she plans to take legal action.
CLICK HERE FOR MORE HEALTH STORIES
The quarantine unit includes 20 single-occupancy rooms with negative air pressure systems and en suite bathroom facilities, along with exercise equipment and Wi-Fi connectivity, according to the University of Nebraska Medical Center’s Global Center for Health Security website.
The Davis Global Center at the University of Nebraska Medical Center campus, which holds the National Quarantine Unit, is seen on May 11, 2026, in Omaha, Nebraska. (Getty Images)
The quarantine order — issued under federal public health authority — was reportedly approved by Jay Bhattacharya, the acting head of the Centers for Disease Control and Prevention.
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
Fox News Digital reached out to the CDC requesting comment.
Including Perryman, a total of 18 American passengers from the MV Hondius have been monitored at the quarantine unit since last week.
Medical staff direct some of the last passengers to be evacuated from the MV Hondius on May 11, 2026, in Tenerife, part of the Canary Islands, Spain. (Chris McGrath/Getty Images)
Seven other passengers who left the ship and returned home prior to the outbreak’s discovery are being monitored by their state and local health departments, per the CDC.
“The reason they’re watching these passengers so carefully is that the incubation period can be very long — up to six weeks — and when symptoms hit, patients can deteriorate very rapidly,” Dr. Marc Siegel, Fox News senior medical analyst, said during a recent episode of “The Faulkner Focus.”
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
“This is not something that spreads easily like COVID, but because the Andes strain has rare person-to-person transmission, public health officials are being extremely cautious,” he added.
At least three people linked to the outbreak aboard the ship have died, while additional passengers have been sickened, according to the World Health Organization.
“This is not something that spreads easily like COVID, but because the Andes strain has rare person-to-person transmission, public health officials are being extremely cautious.”
The federal government last imposed a large-scale quarantine order in January 2020, when nearly 200 Americans evacuated from Wuhan, China, the epicenter of the COVID-19 outbreak. They were required to remain in isolation for two weeks at the March Air Reserve Base in Riverside County, California, per the CDC.
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
“Typically, we don’t hold people against their will unless there is no alternative,” Jennifer Nuzzo, director of the pandemic center at Brown University’s School of Public Health, told The Times.
NEWYou can now listen to Fox News articles!
The Murdoch Children’s Research Institute (MCRI) in Australia will receive a $5 million federal grant to launch a pioneering research team for children’s health.
The grant was announced at MCRI’s 40th anniversary gala in Melbourne on Saturday night.
“For 40 years, MCRI has been a global leader in children’s health research,” Prime Minister Anthony Albanese told guests at the gala, which was attended by 300 of Australia’s most esteemed medical experts, political leaders, philanthropists and sports luminaries.
INTERNATIONAL EFFORT SEEKS NEW TREATMENTS FOR PEDIATRIC HEART DISEASE
“My government is proud to partner with MCRI, so our world-leading researchers have the best opportunities to support healthier childhoods for Australians now and into the future.”
The $5 million will directly support medical research aimed at preventing numerous childhood conditions, including obesity, heart disease, mental health issues and disabilities.
Australian Prime Minister Anthony Albanese speaks at the MCRI gala. (Penny Stephens/Murdoch Children’s Research Institute)
Also announced at the gala, a lead donation from Sarah and Lachlan Murdoch will launch the Horizon Fund — a permanent endowment for MCRI aimed at funding long-term children’s health research and future medical breakthroughs.
THE TEEN ANXIETY EPIDEMIC IN THE US AND AUSTRALIA — AND WHAT TO DO ABOUT IT
The goal is for the fund to raise between $50 million and $100 million in its first year and to reach $200 million within five years.
The fund is designed to back researchers’ immediate priorities while safeguarding long-term capital for future medical breakthroughs in children’s health.
Pictured above, Sarah Murdoch (MCRI co-chair); Jodie Haydon (wife of Prime Minister Albanese); Australian Prime Minister Anthony Albanese; Kathryn North (MCRI director); and Patrick Houlihan (MCRI chair). (Christopher Hopkins/Murdoch Children’s Research Institute)
In 2020, the Murdochs donated $5 million to establish a perpetual fellowship supporting leading researchers in fields including stem cell technology and genomic precision medicine.
Co-founded in 1986 by philanthropist and child health advocate Dame Elisabeth Murdoch and pediatrician and genetics pioneer Professor David Danks, MCRI comprises 1,800 scientists, researchers and clinicians.
CLICK HERE FOR MORE HEALTH STORIES
“Dame Elisabeth’s leadership, along with her values, shaped both the direction and the ethos of the Institute we were to become – for all children to live a healthy and fulfilled life,” said Sarah Murdoch, who is Dame Elisabeth Murdoch’s granddaughter-in-law and MCRI’s global ambassador and board co-chair.
Sarah Murdoch (MCRI co-chair) is pictured with Kathryn North (MCRI director) at the Murdoch Children’s Research Institute 40th Anniversary Gala at the State Library Melbourne. (Penny Stephens/Murdoch Children’s Research Institute)
“With the generosity of a remarkable group of founding donors alongside the Murdoch family – Sir Jack Brockhoff, the Miller family, and The Scobie and Claire Mackinnon Trust – the foundations were laid for an Institute designed to bring our brightest minds, to serve all children, not only in that moment, but for generations to come,” Ms. Murdoch added.
“I see what is possible when foresight, science, commitment, collaboration and heartfelt generosity come together,” she emphasized.
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
“Because behind every breakthrough is a child — a family desperate for answers. A future changed because of the commitment by so many.”
MCRI Director Kathryn North expressed appreciation at the gala to the prime minister for the $5 million grant.
“From the beginning, MCRI has been guided by a simple but powerful purpose: to give all children the opportunity to live a healthy and fulfilled life,” said the MCRI director. (MCRI)
“From the beginning, MCRI has been guided by a simple but powerful purpose: to give all children the opportunity to live a healthy and fulfilled life,” North said.
“It reflects a belief that good health is the foundation for a full life, and that opportunity should never be limited by circumstance.”
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
Professor North mentioned the Institute’s focus on developing therapies for previously incurable diseases.
“We are harnessing the power of human stem cell technologies to grow heart patches, functional mini kidneys, blood and immune cells … to better understand disease, and to develop regenerative therapies using a patient’s own stem cells to replace organ transplants and the risk of rejection,” she said.
The Institute’s next challenge is to address chronic conditions like asthma, obesity, allergies and mental health conditions that can persist for decades. (iStock)
The Institute’s next challenge, North said, is to address chronic conditions like asthma, obesity, allergies and mental health conditions that can persist for decades.
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
“These are big problems that will require significant and ongoing support,” she said. “Through our work globally, we are helping communities raise their expectations to both deliver and receive the sort of healthcare we take for granted.”
“Our ambition now is to translate these partnerships into population-scale solutions that improve the lives of millions of children worldwide,” North added. “This is not simply the next chapter for MCRI – it is the work of building the future of children’s health.”
FDA fast-tracks pancreatic cancer drug daraxonrasib
Family and emergency medicine physician Dr. Janette Nesheiwat discusses how artificial intelligence could help detect pancreatic cancer earlier and the FDA fast-tracking the drug daraxonrasib on ‘Fox Report.’
NEWYou can now listen to Fox News articles!
A new drug for pancreatic cancer is showing promise in early testing.
Daraxonrasib is a daily pill designed to block cancer signals linked to the RAS gene. It has now finished an early-stage clinical trial — the first time it was tested in people — to evaluate both its safety and effectiveness.
The clinical trial, led by the Dana-Farber Cancer Institute and published in The New England Journal of Medicine, tested the drug in 168 patients with advanced pancreatic cancer whose tumors had mutations in the RAS gene. All study participants had previously received at least one chemotherapy treatment.
6 THINGS TO KNOW ABOUT PANCREATIC CANCER AFTER FORMER SENATOR’S DIAGNOSIS
The drug is designed to block multiple active cancer signals that help tumor cells grow. This is especially important because more than 90% of pancreatic cancers carry these harmful mutations, researchers said.
Existing and older drugs that target RAS mutations only work on certain types that are uncommon in pancreatic cancer, such as KRAS mutations.
Daraxonrasib is a daily pill designed to block cancer signals linked to the RAS gene. It has now finished an early-stage clinical trial to evaluate its safety and effectiveness. (iStock)
At the 300-milligram dose — the amount that will be used in larger phase 3 trials — about 30% of patients saw a positive response, researchers noted. Overall, about 90% of patients had their cancer either shrink or stop getting worse.
DEADLY CANCER TYPE LINKED TO OBESITY AND HIGH STRESS LEVELS
There were some side effects reported — most commonly rash, mouth inflammation, nausea and diarrhea.
Lead investigator Dr. Brian Wolpin, director of the Hale Family Center for Pancreatic Cancer Research at Dana-Farber, commented in a press release statement that this development could change the future of cancer care.
About 90% of patients treated with the drug experienced disease control, meaning their cancer was reduced or stabilized. (iStock)
“If supported by data from future clinical trials, daraxonrasib would be a targeted therapy relevant to nearly all patients with advanced pancreatic cancer,” he said.
RISK OF DEADLY CANCER TRIPLES WITH HIDDEN MOUTH BACTERIA, STUDY FINDS
“This trial provides the first published data showing the safety and broad activity of a RAS(ON) multi-selective inhibitor in pancreatic cancer,” Wolpin went on. “If it proves effective in larger clinical trials, it would signify a substantial shift in how this disease is treated.”
In an interview with Fox News Digital, the researcher claimed that daraxonrasib represents “one of the most promising therapy advances we’ve seen in pancreatic cancer.”
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
This is especially significant since pancreatic cancer has had “very few effective therapies” in the past, Wolpin noted.
“The study also showed disease control in approximately 90% of patients with metastatic pancreatic cancer, which is extremely exciting,” he added.
The study does not prove daraxonrasib is superior to standard treatment of chemotherapy, researchers noted. (iStock)
Wolpin noted that while side effects were common, most patients were able to tolerate treatment with “supportive care measures, and very few patients needed to stop therapy due to side effects.”
As this was a phase 1/2 study, it does not “definitively prove” the superiority of daraxonrasib compared to chemotherapy, Wolpin added.
CLICK HERE FOR MORE HEALTH STORIES
“The study did not include a randomized control arm that directly compared daraxonrasib with chemotherapy,” he said. “That being said, the results for daraxonrasib looked substantially better than what we have seen in prior clinical trials of chemotherapy in patients with previously treated metastatic pancreatic cancer.”
It also remains unclear how the drug may perform earlier in the disease, as the trial included patients who had already received prior treatments.
“Additional research is needed to determine how best to sequence or combine therapies to provide the most durable responses and cures,” the lead investigaror sid. (iStock)
For patients and families affected by pancreatic cancer, Wolpin noted that daraxonrasib signals “real momentum” toward effective treatments, but it is still investigational and is not a cure.
“Pancreatic cancer remains a challenging disease, and additional research is needed to determine how best to sequence or combine therapies to provide the most durable responses and cures,” he said.
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
Brian Slomovitz, director of gynecologic oncology and co-chair of the Cancer Research Committee at Mount Sinai Medical Center in Miami Beach, applauded this development in a separate interview with Fox News Digital.
“We are anxiously awaiting the upcoming plenary presentation of RASolute 302 at the ASCO meeting later this month,” said the expert, who was not involved in the study. “Greater than 90% of pancreatic cancers have activation of kRAS, which is a major factor in the development and progression of these cancers.”
“Doubling the survival time in pretreated patients is unprecedented.”
“If the full dataset results that will be reported later this month confirm what was earlier released, I believe this will be one of the most important breakthroughs in all solid tumors,” Slomovitz went on. “Doubling the survival time in pretreated patients is unprecedented.”
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
The doctor added that the “magnitude of benefit” could “reshape the treatment landscape” and “establish a new standard of care.”
“We will need to evaluate the full dataset for efficacy and safety,” Slomovitz added. “I am more than cautiously optimistic, and I am truly excited for our patients and their families that suffer from this dreadful disease.”
-
Kansas6 minutes agoSheriff: Colorado couple jailed in Kansas for transporting drugs
-
Kentucky12 minutes agoTrump-endorsed Ed Gallrein unseats Rep. Thomas Massie in Kentucky GOP primary
-
Louisiana18 minutes agoLouisiana run-rules Marshall, advances to Coastal rematch
-
Maine24 minutes agoSouth Portland discusses use of Flock cameras in city
-
Maryland29 minutes agoNew York man sentenced to 40 years for injuring Maryland deputy during pursuit
-
Michigan36 minutes agoAnti-Semitism increasingly targeting Southeast Michigan communities
-
Massachusetts41 minutes agoMissing Holyoke man identified after body found in Connecticut River
-
Minnesota47 minutes agoInside James Beard Award-nominated Shigeyuki Furukawa’s Kado no Mise
